Therefore, the assessment of the clinical utility of nesfatin-1 and spexin in patients with PWS requires long-term monitoring of the concentrations of these peptides during growth hormone therapy as well as dietary intervention. This evidence concerns the gene NUCB2 and Prader-Willi syndrome.